NASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free RPRX Stock Alerts $26.64 +0.02 (+0.08%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$26.27▼$26.6950-Day Range$26.62▼$30.4552-Week Range$25.92▼$34.65Volume3.12 million shsAverage Volume2.68 million shsMarket Capitalization$15.92 billionP/E Ratio19.88Dividend Yield3.15%Price Target$46.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.5% Upside$46.75 Price TargetShort InterestHealthy3.47% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.81Based on 12 Articles This WeekInsider TradingN/AProj. Earnings Growth9.18%From $4.03 to $4.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.85 out of 5 starsFinance Sector72nd out of 881 stocksPharmaceutical Preparations Industry15th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.47% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 3.42%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 3.16%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has only been increasing its dividend for 4 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.09% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 2.7 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Finance companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search Interest13 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -54% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 9.18% in the coming year, from $4.03 to $4.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 19.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 19.88, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 48.25.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 3.47. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesMay 28 at 3:23 PM | msn.comWhy Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?May 28 at 7:10 AM | globenewswire.comRoyalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 23, 2024 | markets.businessinsider.comHeart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts ObserveMay 22, 2024 | marketwatch.comCytokinetics Falls 10% on Royalty Pharma Transaction, Stock OfferMay 22, 2024 | msn.comCytokinetics to get up to $575M in funding from Royalty PharmaMay 22, 2024 | globenewswire.comRoyalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineMay 20, 2024 | investorplace.com7 Dividend Stocks to Buy at a 52-Week LowMay 13, 2024 | finance.yahoo.comRoyalty Pharma to Present at Upcoming Investor ConferencesMay 12, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter ResultsMay 11, 2024 | finance.yahoo.comOnly Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) DividendMay 11, 2024 | seekingalpha.comRoyalty Pharma: Solid Start Of The Year, Buy ConfirmedMay 10, 2024 | msn.comRoyalty Pharma plc (NASDAQ:RPRX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | uk.finance.yahoo.comQ1 2024 Royalty Pharma PLC Earnings CallMay 9, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 9, 2024 | markets.businessinsider.comRoyalty Pharma Beats Q1 Earnings and Revenue EstimatesMay 9, 2024 | investorplace.comRPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comRoyalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 4, 2024 | finance.yahoo.comRoyalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21April 20, 2024 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21April 19, 2024 | globenewswire.comRoyalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024April 17, 2024 | seekingalpha.comRoyalty Pharma declares $0.21 dividendApril 17, 2024 | finance.yahoo.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 17, 2024 | globenewswire.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 14, 2024 | nasdaq.comRelative Strength Alert For Royalty PharmaApril 11, 2024 | investorplace.com3 Pharma Stocks to Sell in April Before They Crash & BurnSee More Headlines Company Calendar Ex-Dividend for 3/15 Dividend2/15/2024Dividend Payable3/15/2024Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/16/2024Today5/28/2024Dividend Payable6/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Target$46.75 High Stock Price Target$57.00 Low Stock Price Target$38.00 Potential Upside/Downside+75.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio19.87 Forward P/E Ratio6.61 P/E Growth3.47Net Income$1.13 billion Net Margins35.70% Pretax Margin53.03% Return on Equity22.94% Return on Assets13.78% Debt Debt-to-Equity Ratio0.62 Current Ratio12.52 Quick Ratio12.52 Sales & Book Value Annual Sales$2.36 billion Price / Sales6.75 Cash Flow$4.57 per share Price / Cash Flow5.83 Book Value$16.88 per share Price / Book1.58Miscellaneous Outstanding Shares597,440,000Free Float484,521,000Market Cap$15.90 billion OptionableOptionable Beta0.47 Social Links Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 64)Executive VP of Investments & Chief Legal Officer Comp: $4.56MMr. Christopher Hite (Age 56)Vice Chairman & Executive VP Comp: $4.56MDr. Marshall Jonathan Urist M.D. (Age 48)Ph.D., Executive Vice President of Research & Investments Comp: $4.56MMr. Arthur Richard McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 42)Senior VP & Chief Accounting Officer Mr. Eric Cornelius SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZHorizon Therapeutics PublicNASDAQ:HZNPPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsSwedbank ABBought 8,279,900 shares on 5/21/2024Ownership: 1.386%Atria Investments IncBought 39,019 shares on 5/21/2024Ownership: 0.007%Tidal Investments LLCBought 19,834 shares on 5/17/2024Ownership: 0.015%Advisory Resource GroupBought 27,121 shares on 5/17/2024Ownership: 0.005%iA Global Asset Management Inc.Sold 3,981 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price target for 2024? 4 Wall Street analysts have issued 1-year price targets for Royalty Pharma's stock. Their RPRX share price targets range from $38.00 to $57.00. On average, they predict the company's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 75.5% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2024? Royalty Pharma's stock was trading at $28.09 at the beginning of the year. Since then, RPRX shares have decreased by 5.2% and is now trading at $26.64. View the best growth stocks for 2024 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RPRX earnings forecast. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) released its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.02. The biopharmaceutical company earned $568 million during the quarter, compared to analyst estimates of $671.45 million. Royalty Pharma had a net margin of 35.70% and a trailing twelve-month return on equity of 22.94%. During the same period last year, the company posted $1.60 EPS. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma announced a quarterly dividend on Wednesday, April 17th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.21 per share on Friday, June 14th. This represents a $0.84 annualized dividend and a dividend yield of 3.15%. The ex-dividend date is Thursday, May 16th. Read our dividend analysis for RPRX. Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 3.16%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.09% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include Tema Global Royalties ETF (ROYA), SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED) and First Trust Health Care AlphaDEX Fund (FXH). What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.31%), Baillie Gifford & Co. (2.79%), Swedbank AB (1.39%), Homestead Advisers Corp (0.32%), Mitsubishi UFJ Trust & Banking Corp (0.31%) and Janus Henderson Group PLC (0.31%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Scientific Corp Boston and Terrance P Coyne. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPRX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for AIWeiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist My Default Watchlist Adding Royalty Pharma plc You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.